Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth
- 8 June 2011
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 72 (3) , 244-252
Abstract
BACKGROUND Interference of androgen receptor (AR) signaling is a target for prostate cancer (CaP) chemoprevention and treatment. We hypothesize that Zyflamend (ZYF) assert its anti-cancer effect by disrupting AR signaling. We also hypothesize that it may act synergistically with the anti-androgen bicalutimde to inhibit CaP cell growth. METHODS Western blotting, ELISA and reporter assays were done to test ZYF on AR signaling. Semi-quantitative RT-PCR and AR half-life were also examined. Potential synergism between ZYF and bicalutimide were tested via cytotoxicity, colony formation assays, flow cytometry, and Western blotting in the human CAP line, LNCaP and 22RV1. RESULTS ZYF reduced AR protein, mRNA and protein stability levels in LNCaPs. ZYF also reduced both full-length AR protein and truncated AR protein in the 22Rv1 cell line. Nkx3.1 and PSA were also reduced at the mRNA level. PSA promoter activity and secretion were lower after treatment of cells with ZYF. DHT induction of cell proliferation and AR responsiveness revealed reduction of AR, Nkx3.1, and PSA protein were demonstrated with ZYF treatment. Co-treatment with bicalutimide reducing cell growth, induced apoptosis, and reduced Bcl-2 and BclxL, caspase-3 and PARP. Co-treatment also reduced Nkx3.1 and PSA protein. CONCLUSIONS These data indicate that ZYF suppresses cell growth mediated by AR signaling, and suggests that the co-treatment with the anti-androgen bicalutimide and ZYF may be a promising approach for cancer therapy and may demonstrate the mechanism of action of ZYF. Prostate 72:244–252, 2012.Keywords
This publication has 23 references indexed in Scilit:
- Repressive Effects of Resveratrol on Androgen Receptor Transcriptional ActivityPLOS ONE, 2009
- The utility of 5-α reductase inhibitors in the prevention and diagnosis of prostate cancerCurrent Opinion in Urology, 2009
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate CancerCancer Research, 2008
- Zyflamend® reduces LTB 4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[α]anthracene (DMBA)-induced hamster cheek pouch modelCarcinogenesis, 2008
- Steroid Receptor Coactivator-3/AIB1 Promotes Cell Migration and Invasiveness through Focal Adhesion Turnover and Matrix Metalloproteinase ExpressionCancer Research, 2008
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy ResistanceCancer Research, 2008
- Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivoCarcinogenesis, 2008
- Curcumin down regulates homeobox gene NKX3.1 in prostate cancer cell LNCaPActa Pharmacologica Sinica, 2007
- Prostate-specific antigen doubling time as a prognostic marker in prostate cancerNature Reviews Endocrinology, 2005
- DNA Binding-independent Transcriptional Activation by the Androgen Receptor through Triggering of CoactivatorsJournal of Biological Chemistry, 2001